Handelen ADMA Biologics, Inc. - ADMA CFD
Toevoegen aan favorieten- Samenvatting
- Historische gegevens
- Evenementen
- Winst- en verliesrekening
- Balans
- Cash Flow
- Eigendom
Handelsvoorwaarden
| Spread | 0.0304 | ||||||||
|
Overnight-tarief longpositie
Long position overnight fee
Ga naar platform | -0.024068% | ||||||||
|
Overnight-tarief shortpositie
Short position overnight fee
Ga naar platform | 0.001846% | ||||||||
| Tijd van overnight-tarief | 21:00 (UTC) | ||||||||
| Min. verhandelde hoeveelheid | 1 | ||||||||
| Valuta | USD | ||||||||
| Marge | 20% | ||||||||
| Effectenbeurs | United States of America | ||||||||
| Handelscommissie | 0% |
*Information provided by Capital.com
Belangrijkste statistieken
| Prev. Close* | 3.1105 |
| Open* | 3.3797 |
| 1-Jaarlijkse Verandering* | 134.7% |
| Dagelijks bereik* | 3.27 - 3.3797 |
| 52 wekelijks bereik | 1.43-3.98 |
| Weekgemiddelde volume (10 dagen) | 3.40M |
| Gemiddeld volume (3 maanden) | 50.84M |
| Marktkapitalisatie | 722.95M |
| P/E Ratio | -100.00K |
| Uitstaande Aandelen | 222.16M |
| Omzet | 130.48M |
| EPS | -0.37 |
| Dividend (opbrengst %) | N/A |
| Beta | 0.93 |
| Volgende inkomsten datum | May 9, 2023 |
Alle gegevens zijn afkomstig van Refinitiv, behalve de gegevens gemarkeerd met een sterretje, die zijn afkomstig van Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Slotkoers | Change | Change (%) | Openingskoers | High | Low |
|---|---|---|---|---|---|---|
| Mar 24, 2023 | 3.3198 | 0.0299 | 0.91% | 3.2899 | 3.4096 | 3.2301 |
| Mar 23, 2023 | 3.1105 | 0.0997 | 3.31% | 3.0108 | 3.1204 | 3.0107 |
| Mar 22, 2023 | 2.9809 | -0.0697 | -2.28% | 3.0506 | 3.0905 | 2.9809 |
| Mar 21, 2023 | 3.0706 | 0.0300 | 0.99% | 3.0406 | 3.1703 | 3.0406 |
| Mar 20, 2023 | 3.0507 | -0.0299 | -0.97% | 3.0806 | 3.1005 | 2.9310 |
| Mar 17, 2023 | 3.0606 | -0.0298 | -0.96% | 3.0904 | 3.1204 | 3.0207 |
| Mar 16, 2023 | 3.1105 | 0.0300 | 0.97% | 3.0805 | 3.1703 | 3.0506 |
| Mar 15, 2023 | 3.1105 | 0.0001 | 0.00% | 3.1104 | 3.1902 | 3.0806 |
| Mar 14, 2023 | 3.2002 | -0.0099 | -0.31% | 3.2101 | 3.2600 | 3.1603 |
| Mar 13, 2023 | 3.1803 | 0.1696 | 5.63% | 3.0107 | 3.2201 | 3.0008 |
| Mar 10, 2023 | 3.0806 | -0.1594 | -4.92% | 3.2400 | 3.2600 | 3.0307 |
| Mar 9, 2023 | 3.2600 | -0.1496 | -4.39% | 3.4096 | 3.4395 | 3.2102 |
| Mar 8, 2023 | 3.3896 | 0.0100 | 0.30% | 3.3796 | 3.4495 | 3.3497 |
| Mar 7, 2023 | 3.3797 | 0.0200 | 0.60% | 3.3597 | 3.4495 | 3.2998 |
| Mar 6, 2023 | 3.3398 | -0.0697 | -2.04% | 3.4095 | 3.4295 | 3.2999 |
| Mar 3, 2023 | 3.3996 | -0.0897 | -2.57% | 3.4893 | 3.4893 | 3.3697 |
| Mar 2, 2023 | 3.4395 | -0.0698 | -1.99% | 3.5093 | 3.5392 | 3.4395 |
| Mar 1, 2023 | 3.5292 | -0.0099 | -0.28% | 3.5391 | 3.6489 | 3.5292 |
| Feb 28, 2023 | 3.5392 | 0.0798 | 2.31% | 3.4594 | 3.5890 | 3.4594 |
| Feb 27, 2023 | 3.4694 | 0.0599 | 1.76% | 3.4095 | 3.5192 | 3.3996 |
ADMA Biologics, Inc. Events
| Tijd (UTC) (UTC) | Land | Evenement |
|---|---|---|
| No events scheduled | ||
- Jaarlijks
- Per kwartaal
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Totale inkomsten | 80.9426 | 42.2198 | 29.3491 | 16.9853 | 22.7606 |
| Inkomsten | 80.9426 | 42.2198 | 29.3491 | 16.9853 | 22.7606 |
| Kosten van opbrengsten, totaal | 79.7693 | 61.2914 | 39.5042 | 42.1946 | 29.1643 |
| Brutowinst | 1.17329 | -19.0716 | -10.1552 | -25.2094 | -6.40376 |
| Totale bedrijfskosten | 139.316 | 106.143 | 80.7359 | 77.2742 | 63.2808 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 55.1856 | 39.2209 | 28.0804 | 30.3085 | 24.5966 |
| Onderzoek & Ontwikkeling | 3.64606 | 5.90701 | 2.34385 | 3.92612 | 6.22959 |
| Ongebruikelijke uitgaven (inkomsten) | 0 | -0.9918 | 9.9625 | 0 | 2.05561 |
| Bedrijfsresultaat | -58.3737 | -63.9231 | -51.3868 | -60.2889 | -40.5202 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | -13.0223 | -11.6969 | -8.19259 | -5.32738 | -3.22862 |
| Overige, Netto | -0.25158 | -0.12853 | -0.22732 | -0.12712 | -0.01014 |
| Netto inkomen voor belastingen | -71.6476 | -75.7486 | -48.2793 | -65.7434 | -43.759 |
| Netto inkomen na belastingen | -71.6476 | -75.7486 | -48.2793 | -65.7434 | -43.759 |
| Netto inkomen voor extra. Posten | -71.6476 | -75.7486 | -48.2793 | -65.7434 | -43.759 |
| Netto inkomen | -71.6476 | -75.7486 | -48.2793 | -65.7434 | -43.759 |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -71.6476 | -75.7486 | -48.2793 | -65.7434 | -43.759 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -71.6476 | -75.7486 | -48.2793 | -65.7434 | -43.759 |
| Verwaterd Netto Inkomen | -71.6476 | -75.7486 | -48.2793 | -65.7434 | -43.759 |
| Verwaterd Gewogen Gemiddelde Aandelen | 139.579 | 86.1451 | 54.3481 | 45.1889 | 22.896 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -0.51331 | -0.87931 | -0.88833 | -1.45486 | -1.9112 |
| Verwaterde Genormaliseerde Winst per Aandeel | -0.51331 | -0.89083 | -0.91713 | -1.45486 | -1.82142 |
| Depreciation / Amortization | 0.71535 | 0.71535 | 0.84494 | 0.84494 | 1.23467 |
| Totale buitengewone posten | 0 | ||||
| Gain (Loss) on Sale of Assets | 0 | 11.5274 |
| Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | |
|---|---|---|---|---|---|
| Totale inkomsten | 41.0901 | 33.905 | 29.1031 | 26.3829 | 20.6805 |
| Inkomsten | 41.0901 | 33.905 | 29.1031 | 26.3829 | 20.6805 |
| Kosten van opbrengsten, totaal | 31.4335 | 26.1356 | 25.441 | 22.8714 | 20.2952 |
| Brutowinst | 9.65664 | 7.7694 | 3.66204 | 3.51149 | 0.38534 |
| Totale bedrijfskosten | 50.4069 | 43.0798 | 50.5881 | 39.5741 | 35.1176 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 17.7526 | 15.8919 | 17.6742 | 15.7948 | 13.873 |
| Onderzoek & Ontwikkeling | 1.04195 | 0.87339 | 0.62411 | 0.72899 | 0.77056 |
| Depreciation / Amortization | 0.17884 | 0.17884 | 0.17884 | 0.17884 | 0.17884 |
| Bedrijfsresultaat | -9.31673 | -9.17474 | -21.485 | -13.1912 | -14.4371 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | -5.57313 | -4.57075 | -3.35597 | -3.31343 | -3.29442 |
| Overige, Netto | -0.00964 | -0.01942 | -0.16688 | -0.1448 | 0.01855 |
| Netto inkomen voor belastingen | -14.8995 | -13.7649 | -25.0079 | -16.6494 | -17.7129 |
| Netto inkomen na belastingen | -14.8995 | -13.7649 | -25.0079 | -16.6494 | -17.7129 |
| Netto inkomen voor extra. Posten | -14.8995 | -13.7649 | -25.0079 | -16.6494 | -17.7129 |
| Netto inkomen | -14.8995 | -13.7649 | -25.0079 | -16.6494 | -17.7129 |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -14.8995 | -13.7649 | -25.0079 | -16.6494 | -17.7129 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -14.8995 | -13.7649 | -25.0079 | -16.6494 | -17.7129 |
| Verwaterd Netto Inkomen | -14.8995 | -13.7649 | -25.0079 | -16.6494 | -17.7129 |
| Verwaterd Gewogen Gemiddelde Aandelen | 196.384 | 196.353 | 195.872 | 181.267 | 133.77 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -0.07587 | -0.0701 | -0.12767 | -0.09185 | -0.13241 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Verwaterde Genormaliseerde Winst per Aandeel | -0.07587 | -0.0701 | -0.09362 | -0.09185 | -0.13241 |
| Ongebruikelijke uitgaven (inkomsten) | 0 | 0 | 6.66994 | 0 |
- Jaarlijks
- Per kwartaal
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Totaal vlottende activa | 208.729 | 153.741 | 85.8204 | 44.5296 | 62.3416 |
| Geldmiddelen en kortetermijnbeleggingen | 51.0891 | 55.9212 | 26.7521 | 22.7549 | 43.1076 |
| Geldmiddelen & Equivalenten | 51.0891 | 55.9212 | 26.7521 | 22.7549 | 43.1076 |
| Korte Termijn Investeringen | |||||
| Totale Vorderingen, Netto | 28.5769 | 13.2373 | 3.46992 | 1.39244 | 3.88015 |
| Accounts Receivable - Trade, Net | 28.5769 | 13.2373 | 3.46992 | 1.39244 | 3.88015 |
| Total Inventory | 124.724 | 81.5356 | 53.0647 | 18.6162 | 12.6282 |
| Prepaid Expenses | 4.33925 | 3.04647 | 2.53359 | 1.76616 | 1.22565 |
| Total Assets | 276.253 | 207.673 | 127.091 | 88.8765 | 108.019 |
| Property/Plant/Equipment, Total - Net | 58.1977 | 45.8523 | 33.1413 | 30.1157 | 30.4669 |
| Property/Plant/Equipment, Total - Gross | 71.4696 | 54.7162 | 38.8663 | 33.5368 | 31.7528 |
| Accumulated Depreciation, Total | -13.2718 | -8.86394 | -5.72496 | -3.42103 | -1.28592 |
| Other Long Term Assets, Total | 4.0674 | 2.10698 | 1.44004 | 6.69725 | 6.83155 |
| Total Current Liabilities | 30.3783 | 19.9474 | 14.0279 | 9.62505 | 9.44018 |
| Accounts Payable | 12.4294 | 11.0737 | 9.17459 | 5.90039 | 5.92087 |
| Accrued Expenses | 16.7941 | 8.73083 | 4.71047 | 3.58182 | 3.37648 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | |||||
| Other Current Liabilities, Total | 1.15482 | 0.14283 | 0.14283 | 0.14283 | 0.14283 |
| Total Liabilities | 135.08 | 119.424 | 100.898 | 69.1061 | 67.6861 |
| Total Long Term Debt | 94.8662 | 92.9689 | 83.1992 | 44.075 | 42.9709 |
| Long Term Debt | 94.8662 | 92.9689 | 83.1992 | 44.075 | 42.9709 |
| Other Liabilities, Total | 9.8356 | 6.50774 | 3.67047 | 15.406 | 15.275 |
| Total Equity | 141.173 | 88.2494 | 26.1931 | 19.7704 | 40.3328 |
| Common Stock | 0.01958 | 0.01049 | 0.00593 | 0.00464 | 0.00453 |
| Additional Paid-In Capital | 553.266 | 428.704 | 290.904 | 236.203 | 191.022 |
| Retained Earnings (Accumulated Deficit) | -412.113 | -340.465 | -264.717 | -216.437 | -150.694 |
| Total Liabilities & Shareholders’ Equity | 276.253 | 207.673 | 127.091 | 88.8765 | 108.019 |
| Total Common Shares Outstanding | 195.814 | 104.903 | 59.3184 | 46.3531 | 36.7255 |
| Other Current Assets, Total | 0 | 1.5 | |||
| Goodwill, Net | 3.52951 | 3.52951 | 3.52951 | 3.52951 | 3.52951 |
| Intangibles, Net | 1.72877 | 2.44412 | 3.15947 | 4.00441 | 4.84935 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Totaal vlottende activa | 239.8 | 208.729 | 174.785 | 171.355 | 177.277 |
| Geldmiddelen en kortetermijnbeleggingen | 69.505 | 51.0891 | 34.4106 | 42.409 | 61.9657 |
| Geldmiddelen & Equivalenten | 69.505 | 51.0891 | 34.4106 | 42.409 | 61.9657 |
| Totale Vorderingen, Netto | 25.6296 | 28.5769 | 20.3926 | 23.5446 | 15.362 |
| Accounts Receivable - Trade, Net | 25.6296 | 28.5769 | 20.3926 | 23.5446 | 15.362 |
| Total Inventory | 139.146 | 124.724 | 114.123 | 99.6997 | 94.1462 |
| Prepaid Expenses | 5.5193 | 4.33925 | 5.85905 | 5.70186 | 5.80261 |
| Total Assets | 308.033 | 276.253 | 238.64 | 232.814 | 235.667 |
| Property/Plant/Equipment, Total - Net | 60.3271 | 58.1977 | 55.0847 | 53.316 | 50.3729 |
| Property/Plant/Equipment, Total - Gross | 75.0076 | 71.4696 | 67.2809 | 64.2715 | 60.2769 |
| Accumulated Depreciation, Total | -14.6804 | -13.2718 | -12.1962 | -10.9555 | -9.90401 |
| Goodwill, Net | 3.52951 | 3.52951 | 3.52951 | 3.52951 | 3.52951 |
| Intangibles, Net | 1.54993 | 1.72877 | 1.90761 | 2.08645 | 2.26528 |
| Other Long Term Assets, Total | 2.82575 | 4.0674 | 3.33351 | 2.52666 | 2.22278 |
| Total Current Liabilities | 31.5665 | 30.3783 | 32.3372 | 18.1864 | 21.2057 |
| Accounts Payable | 14.1151 | 12.4294 | 17.2828 | 6.16747 | 12.1529 |
| Accrued Expenses | 14.2198 | 16.7941 | 13.0301 | 10.7303 | 8.14151 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 3.23159 | 1.15482 | 2.02432 | 1.28866 | 0.91137 |
| Total Liabilities | 181.099 | 135.08 | 135.86 | 121.22 | 123.163 |
| Total Long Term Debt | 138.423 | 94.8662 | 94.363 | 93.877 | 93.4127 |
| Long Term Debt | 138.423 | 94.8662 | 94.363 | 93.877 | 93.4127 |
| Other Liabilities, Total | 11.1099 | 9.8356 | 9.15999 | 9.15685 | 8.54454 |
| Total Equity | 126.933 | 141.173 | 102.78 | 111.594 | 112.504 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.01964 | 0.01958 | 0.01383 | 0.01319 | 0.0123 |
| Additional Paid-In Capital | 564.034 | 553.266 | 498.23 | 489.331 | 471.337 |
| Retained Earnings (Accumulated Deficit) | -437.121 | -412.113 | -395.463 | -377.75 | -358.845 |
| Total Liabilities & Shareholders’ Equity | 308.033 | 276.253 | 238.64 | 232.814 | 235.667 |
| Total Common Shares Outstanding | 196.348 | 195.814 | 138.314 | 131.872 | 123.045 |
- Jaarlijks
- Per kwartaal
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Netto-inkomen/Beginsaldo | -71.6476 | -75.7486 | -48.2793 | -65.7434 | -43.759 |
| Geldmiddelen uit Operationele Activiteiten | -112.369 | -102.003 | -76.1935 | -62.6787 | -37.2718 |
| Geldmiddelen uit Operationele Activiteiten | 5.4955 | 3.94229 | 3.25815 | 3.4464 | 2.6923 |
| Niet-Geldelijke Posten | 5.46355 | 3.58462 | 2.33044 | 3.30681 | 4.07714 |
| Contant Betaalde Rente | 11.1595 | 10.2676 | 8.11223 | 4.39997 | 2.29359 |
| Veranderingen in het Operationeel Kapitaal | -51.6804 | -33.7813 | -33.5028 | -3.68844 | -0.28224 |
| Geldmiddelen uit Investeringsactiviteiten | -13.5113 | -12.7247 | -3.81184 | -2.0956 | 15.2139 |
| Kapitaaluitgaven | -13.5113 | -12.7267 | -3.81184 | -2.0956 | -2.67633 |
| Overige Cash Flow investeringsposten, Totaal | 0 | 0.002 | 0 | 17.8902 | |
| Geldmiddelen uit Financieringsactiviteiten | 121.048 | 143.897 | 80.0026 | 42.9216 | 60.7506 |
| Financiering van Cash Flow Posten | -0.0616 | -0.83 | -10.9395 | 0 | -3.44017 |
| Uitgifte (Aflossing) van aandelen, netto | 121.144 | 131.209 | 48.4721 | 42.9578 | 39.2074 |
| Uitgifte (Aflossing) van Schulden, Netto | -0.0343 | 13.5179 | 42.47 | -0.03628 | 24.9834 |
| Nettowijziging in Geldmiddelen | -4.83203 | 29.169 | -0.00272 | -21.8527 | 38.6927 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -25.0079 | -71.6476 | -54.9982 | -37.2852 | -18.3799 |
| Cash From Operating Activities | -26.0134 | -112.369 | -78.9037 | -65.4914 | -33.2291 |
| Cash From Operating Activities | 1.59022 | 5.4955 | 3.97779 | 2.55562 | 1.22963 |
| Non-Cash Items | 8.86246 | 5.46355 | 3.64236 | 2.50146 | 1.19026 |
| Cash Interest Paid | 2.52599 | 11.1595 | 8.34697 | 5.53428 | 2.75196 |
| Changes in Working Capital | -11.4582 | -51.6804 | -31.5257 | -33.2632 | -17.2691 |
| Cash From Investing Activities | -2.84209 | -13.5113 | -9.8354 | -7.04674 | -2.57116 |
| Capital Expenditures | -2.84209 | -13.5113 | -9.8354 | -7.04674 | -2.57116 |
| Other Investing Cash Flow Items, Total | 0 | 0 | 0 | 0 | |
| Cash From Financing Activities | 47.2713 | 121.048 | 67.2286 | 59.0259 | 41.8448 |
| Financing Cash Flow Items | -4.46973 | -0.0616 | -0.0616 | -0.05931 | -0.05931 |
| Issuance (Retirement) of Stock, Net | 0 | 121.144 | 67.3157 | 59.1021 | 41.9125 |
| Issuance (Retirement) of Debt, Net | 51.7411 | -0.0343 | -0.02551 | -0.01686 | -0.00836 |
| Net Change in Cash | 18.4158 | -4.83203 | -21.5106 | -13.5122 | 6.04456 |
| Naam investeerder | Type investeerder | Percentage uitstaand | Aandelen in bezit | Wijziging aandelen | Datum bezit | Omzetcijfer |
|---|---|---|---|---|---|---|
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 6.1941 | 13488055 | 1946140 | 2022-12-31 | LOW |
| Perceptive Advisors LLC | Private Equity | 5.465 | 11900255 | 966868 | 2022-12-31 | MED |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 5.0548 | 11007209 | 1583787 | 2022-12-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.9762 | 10835875 | 1545176 | 2022-12-31 | LOW |
| NWQ Investment Management Company, LLC | Investment Advisor/Hedge Fund | 4.8736 | 10612600 | 3727960 | 2021-12-31 | LOW |
| D. E. Shaw & Co., L.P. | Hedge Fund | 3.9073 | 8508409 | 2664613 | 2022-12-31 | MED |
| Stonepine Capital Management, LLC | Investment Advisor/Hedge Fund | 3.1871 | 6940000 | 1940000 | 2022-12-31 | MED |
| Magnetar Capital Partners LP | Investment Advisor/Hedge Fund | 2.8414 | 6187316 | 1815908 | 2022-12-31 | HIGH |
| AWM Investment Company, Inc. | Investment Advisor/Hedge Fund | 2.7623 | 6015000 | 1000000 | 2022-12-31 | LOW |
| Millennium Management LLC | Hedge Fund | 2.4324 | 5296781 | 3569778 | 2022-12-31 | HIGH |
| Nuveen Asset Management, LLC | Investment Advisor/Hedge Fund | 1.8845 | 4103514 | -883582 | 2022-12-31 | LOW |
| Velan Capital Investment Management LP | Investment Advisor/Hedge Fund | 1.8369 | 4000000 | -1269155 | 2022-12-31 | MED |
| Invesco Advisers, Inc. | Investment Advisor | 1.7886 | 3894678 | 813693 | 2022-12-31 | LOW |
| Aisling Capital, LLC | Private Equity | 1.6604 | 3615671 | 0 | 2022-04-15 | |
| Nuveen LLC | Pension Fund | 1.5839 | 3448993 | -267644 | 2022-12-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.5553 | 3386852 | 100723 | 2022-12-31 | LOW |
| Two Sigma Investments, LP | Hedge Fund | 1.364 | 2970124 | 1530127 | 2022-12-31 | HIGH |
| Altium Capital Management LP | Investment Advisor/Hedge Fund | 1.318 | 2870000 | -13710 | 2022-12-31 | HIGH |
| Morgan Stanley & Co. LLC | Research Firm | 1.2959 | 2821903 | 558990 | 2022-12-31 | MED |
| Caligan Partners, LP | Hedge Fund | 1.2289 | 2676093 | -8217144 | 2022-12-31 | MED |
Waarom Capital.com? De cijfers spreken voor zichzelf.
Capital.com Group500K+
Handelaren
92K+
Actieve klanten per maand
$53M+
Maandelijks beleggingsvolume
$30M+
Opgenomen per maand
Handelscalculator
Bereken uw virtuele winst- en verliesrekening indien u een CFD-positie had geopend op een bepaalde datum (kies een datum) en gesloten op een andere datum (kies een datum).
Handelscommissie
0
- 1:1
Hefboom
1:1
- 20
- 100
- 500
- 1000
- 10000
Investering
Positiegrootte (hefboomwerking x investering):
Openingskoers
Slotkoers
Short Long
ADMA Biologics, Inc. Company profile
Over ADMA Biologics, Inc.
ADMA Biologics, Inc. is een biofarmaceutisch bedrijf. Het bedrijf ontwikkelt, produceert en verkoopt speciale biologische geneesmiddelen op basis van plasma voor de behandeling en preventie van infectieziekten. Het bedrijf houdt zich bezig met de ontwikkeling en commercialisering van menselijk plasma en van plasma afgeleide therapeutica. De patiënten van het bedrijf zijn onder meer immuungecompromitteerde personen die lijden aan een onderliggende immuundeficiëntiestoornis en immuunsuppressie om medische redenen. De kandidaat-producten omvatten BIVIGAM, een intraveneus immuunglobulineproduct (IVIG) voor de behandeling van primaire humorale immunodeficiëntie (PI); ASCENIV, een IVIG-product voor de behandeling van PI, en Nabi-HB voor de behandeling van acute blootstelling aan bloed dat hepatitis B-oppervlakte-antigeen (HBsAg) bevat. Haar dochteronderneming ADMA BioCenters exploiteert faciliteiten voor de inzameling van bronplasma in de Verenigde Staten. Haar segment Plasma Collection Centers levert een deel van haar bloedplasma voor de productie van haar kandidaat-producten.
| Industry: | Biopharmaceuticals |
C/O Adma Biologics, Inc.
465 State Route 17
07446
Winst- en verliesrekening
- Annual
- Quarterly
Mensen bekijken ook
Nog steeds op zoek naar een broker die u kunt vertrouwen?
Sluit u aan bij de 500.000+ handelaren die er wereldwijd voor kozen om met Capital.com te handelen